{"id":"preservative-free-timolol-maleate","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or discomfort"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Systemic beta-blocker effects (bradycardia, bronchospasm in susceptible patients)"}]},"_chembl":{"chemblId":"CHEMBL1200870","moleculeType":"Small molecule","molecularWeight":"432.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Timolol blocks beta-1 and beta-2 adrenergic receptors in the ciliary body of the eye, which reduces the rate of aqueous humor formation. This leads to a decrease in intraocular pressure, making it effective for treating glaucoma and ocular hypertension. The preservative-free formulation minimizes ocular surface irritation and is suitable for patients with sensitive eyes or those using multiple topical medications.","oneSentence":"Timolol maleate is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:04.044Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT06030193","phase":"PHASE2","title":"Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qlaris Bio, Inc.","startDate":"2025-08-13","conditions":"Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral, Low-Tension Glaucoma, Unspecified Eye","enrollment":36},{"nctId":"NCT03193333","phase":"PHASE3","title":"PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2017-11-06","conditions":"Primary Open-angle Glaucoma","enrollment":51},{"nctId":"NCT04857827","phase":"PHASE2","title":"A Study to Evaluate Safety and Tolerability of QLS-101 in NTG","status":"COMPLETED","sponsor":"Qlaris Bio, Inc.","startDate":"2021-09-15","conditions":"Normal Tension Glaucoma (NTG)","enrollment":30},{"nctId":"NCT04830397","phase":"PHASE2","title":"Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).","status":"COMPLETED","sponsor":"Qlaris Bio, Inc.","startDate":"2021-03-31","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":84},{"nctId":"NCT05857267","phase":"PHASE4","title":"Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety","status":"COMPLETED","sponsor":"Laboratorios Poen","startDate":"2023-03-07","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":84},{"nctId":"NCT02053298","phase":"PHASE4","title":"Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2014-01","conditions":"Open Angle Glaucoma","enrollment":30},{"nctId":"NCT04702789","phase":"PHASE4","title":"Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-10-19","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":28},{"nctId":"NCT03822559","phase":"PHASE3","title":"A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2019-01-20","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":219},{"nctId":"NCT04828057","phase":"","title":"Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2021-09-01","conditions":"Ocular Surface Disease, Primary Open Angle Glaucoma","enrollment":50},{"nctId":"NCT04673604","phase":"NA","title":"From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2018-05-06","conditions":"Glaucoma, Ocular Surface Disease","enrollment":42},{"nctId":"NCT04891588","phase":"NA","title":"Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD","status":"UNKNOWN","sponsor":"Klinički Bolnički Centar Zagreb","startDate":"2021-03-08","conditions":"Primary Open-angle Glaucoma, Ocular Hypertension","enrollment":50},{"nctId":"NCT03612817","phase":"PHASE4","title":"Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2017-01","conditions":"Glaucoma, Open-Angle","enrollment":42},{"nctId":"NCT02802137","phase":"PHASE4","title":"24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2015-03","conditions":"Glaucoma, Ocular Surface Disease","enrollment":43},{"nctId":"NCT03966365","phase":"PHASE1","title":"Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2019-05-02","conditions":"Glaucoma","enrollment":24},{"nctId":"NCT01533376","phase":"PHASE1","title":"Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol","status":"TERMINATED","sponsor":"Wills Eye","startDate":"2012-02","conditions":"Sturge Weber Syndrome, Port-wine Mark","enrollment":3},{"nctId":"NCT01254604","phase":"PHASE3","title":"Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":190},{"nctId":"NCT01228149","phase":"PHASE4","title":"COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy","status":"COMPLETED","sponsor":"Katrin Lorenz","startDate":"2010-08","conditions":"Glaucoma","enrollment":62},{"nctId":"NCT01026831","phase":"PHASE3","title":"Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-01-06","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":643},{"nctId":"NCT00545064","phase":"PHASE4","title":"Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-05-23","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":176},{"nctId":"NCT01923714","phase":"","title":"Impact of a Tolerability Switch to Dorzolamide/Timolol Preservative-free Fixed Combination on Ocular Surface Symptoms","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2011-08","conditions":"Open Angle Glaucoma","enrollment":103},{"nctId":"NCT01292460","phase":"PHASE3","title":"Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2011-02","conditions":"Ocular Hypertension, Open-angle Glaucoma","enrollment":600},{"nctId":"NCT01434888","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2011-09","conditions":"Healthy Volunteers","enrollment":15},{"nctId":"NCT01306461","phase":"PHASE3","title":"Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2011-03","conditions":"Ocular Hypertension, Open-angle Glaucoma","enrollment":401}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Preservative-Free Timoptic"],"phase":"phase_3","status":"active","brandName":"Preservative-Free Timolol maleate","genericName":"Preservative-Free Timolol maleate","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Timolol maleate is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}